Female patients (n = 20) with osteoporosis, aged 66±5 yr were studied during a 24-h infusion of parathyroid hormone at a rate of 0.5 IU equivalents/kg* h, and then during a 28-d period of subcutaneous injections, at a dose of 800 IU equivalents per day. Thereafter halfthe patients received subcutaneous injections of calcitonin, 75 U/d for 42 d, and all patients were followed to the end of a 90-d cycle. Biochemical markers of bone formation (serum alkaline phosphatase, osteocalcin, and the carboxy-terminal extension peptide of procollagen 1 ) and bone resorption (fasting urine calcium, hydroxyproline, and deoxypyridinoline) were compared during treatment by the intravenous and subcutaneous route of PTH administration, and subsequently during calcitonin therapy. During intravenous PTH infusion there were significant reductions in all three bone formation markers, despite expected rises in urinary calcium and hydroxyproline. By contrast, the circulating markers of bone formation increased rapidly by > 100% of baseline values during daily PTH injections (P <0.001). Significant increases in bone resorption markers were only seen at the end of the 28 d of injections, but were < 100% over baseline values, (P < 0.05). Quantitative bone histomorphometry from biopsies obtained after 28 d of PTH treatment confirmed that bone formation at both the cellular and tissue levels were two to five times higher than similar indices measured in a control group of biopsies from untreated osteoporotic women. Subsequent treatment of these patients with calcitonin showed no significant changes in the biochemical markers of bone formation and only a modest attenuation of bone resorption.
Synthetic parathyroid hormone (PTH) fragments have been used as therapeutic agents to augment bone mass in osteoporotic patients since the early 1 970s ( 1 ) . Most studies have utilized the hormone as an anabolic agent, giving the drug by subcutaneous daily injection for months at a time (1) (2) (3) (4) , and all have reported increases in bone mass, whether defined by bone histomorphometric or densitometric outcomes. Other investigators have used short cycles of PTH therapy for several weeks at a time (5) (6) (7) (8) . In part these alternative regimens have exploited the property of PTH to act as an activator of bone remodeling (8) , utilizing repeating cycles of activation-depression treatment-free periods (ADFR) . However, none of the protocols reported so far can be considered as true ADFR therapies as originally proposed by Frost (9) ; rather they are sequential protocols using cycles ofboth an activator and depressor of bone remodeling, hoping to exploit the advantages of such agents without incurring their disadvantages.
Surprisingly, there have been few attempts to evaluate the biochemical response ofthe osteoporotic skeleton to PTH during therapeutic trials, either in terms of circulating markers of bone formation or urinary excretion of bone resorption markers. In a preliminary evaluation of a cyclical protocol using a 1 4-d period of PTH therapy, followed sequentially by 56 d of calcitonin injections, Hodsman and Fraher (7) reported significant increases in serum alkaline phosphatase, but only small changes in serum osteocalcin (two markers ofbone osteoblast activity), and concluded that the dose ofPTH used in that study (400 IU equivalents per day) should be increased in future protocols using cyclical PTH therapy (7) .
The anabolic effects of PTH upon bone have now been confirmed in numerous animal models (10) (11) (12) (13) (14) (15) (16) (17) . However, this presents a paradox, in that most studies of PTH action on osteoblasts in vitro suggest that this hormone is anti-anabolic. Thus continuous exposure of osteoblasts to PTH in the culture medium results in suppression ofalkaline phosphatase ( 18, 19) and osteocalcin (20, 21 ) release. Tam et al. ( 11 ) first suggested that the biological actions of PTH in vivo were primarily anabolic only when the hormone was given by intermittent injection, but resorptive if given by continuous infusion. The reasons for this functional discrepancy are unknown. Clearly these differences in the pharmacological actions of PTH are crucial to an understanding of the anabolic actions of PTH, ifthese are to be exploited in the future as a therapy for osteoporosis.
There are now several known biochemical markers either of osteoblast function or bone formation including serum alkaline phosphatase, osteocalcin, and the carboxy-terminal extension peptide of procollagen I (PlCP).' In addition to urinary excretion of hydroxyproline (OH-proline) as a marker of bone resorption, the more recently described pyridinium cross-links ofcollagen may be more specific and sensitive markers of bone resorption (22) (23) (24) .
In this report we have evaluated this panel of bone formation and resorption markers in a group of 20 osteoporotic patients entering a clinical trial involving cycles of daily PTH injections followed sequentially by calcitonin (or placebo-calcitonin) injections. Our first objective was to compare the responses of these markers after continuous PTH infusion, with those documented after intermittent subcutaneous injections, to determine whether the different pharmacological responses observed in animals according to the route of administration are also seen in elderly humans. Our second objective was to determine whether surrogate markers of bone turnover could be used to predict responses in bone to calciotropic hormones by comparing them to changes observed in bone biopsies.
Methods

Patients
All patients recruited to this study had a clinical diagnosis of type I osteoporosis (25) ; primary medical problems associated with osteoporosis, including steroid therapy, adrenal or thyroid disease, and neoplastic conditions were excluded by appropriate history and biochemical tests. Radiological evidence for vertebral compression fractures was present in all subjects. All patients signed informed consent to the treatment and investigational protocol, and the study was approved by the Institutional Review Board for Research Involving Human Subjects, at the University of Western Ontario. After signing informed consent patients were randomly assigned to one of two treatment protocols, which had been modified from the experience gained in an earlier pilot study with cyclical PTH and calcitonin (7, 8 The 20 patients reported here comprise the initial entrants into a 2-yr study protocol, designed to evaluate whether cyclical PTH, or cycles of PTH with sequential calcitonin have beneficial effects on vertebral, femoral neck, and radial bone mineral density. The study design seeks to address the need for an anti-resorptive agent in protecting cortical bone from any "catabolic" effects induced by PTH. Because of the long duration of the overall study, and the experimental nature of the hypothesis, a full factorial design (to include groups receiving only placebo or calcitonin) was considered unacceptable by the Institutional Review Board.
Allocation of patients to the two groups was masked by treating patients in group 1 with placebo injections of calcitonin for the same 42-d period, and the code for the groups was maintained in a single dispensing pharmacy at St. Joseph's Health Centre, London, ON. All patients in groups 1 and 2 were then followed for a further 20-d treatment-free interval to complete a cycle period totaling 90 d. At entry, all patients had a standardized 24-h infusion of hPTH ( 1-34) in a dose of 0.5 IU equivalents (8 pmol)/kg * h as previously described (7); in addition to the serum and urine biochemistry described below all patients underwent a transiliac bone biopsy on day 32 of the protocol after in vivo administration of tetracycline on days 12-14 and days 26-28. Both hPTH [Parathar] and calcitonin [Calcimar] were supplied for the sole purpose of this study by Rhone-Poulenc-Rorer, Montreal, PQ, Canada. It was impracticable to obtain baseline bone biopsies in the study patients before entry to the protocol. Thus the bone histomorphometry data obtained on day 32 was compared with a representative control group of 15 women enrolled into a pilot study of cyclical PTH and calcitonin therapy (7, 8) . The inclusion and exclusion criteria for both studies were identical, as were the analytical techniques used for quantifying the bone biopsies.
Methods
Daily dietary calcium intakes were estimated for both the study patients and the control group who provided baseline histomorphometric data, using a standardized dietary questionnaire. The number of vertebral compression fractures was tabulated for both study and control groups from standardized lateral spinal x-rays, counting a "fracture" for any vertebra having 2 20% deformity in either the mid-or anterior vertebral height. Vertebral bone mineral density (BMD) was measured in all study patients at baseline, using a Hologic QDR 1000 dual-energy x-ray densitometer (Hologic Inc., Waltham, MA), although the degree of osteopenia measured by this technique did not constitute an inclusion criterion. By way of comparison, vertebral BMD data are shown for the control group; however, these subjects were all measured 2 yr earlier by a Lunar DP3 dual-photon densitometer (Lunar Corp., Madison, WI). Because both instruments were in one center, we are able to convert Lunar BMD data into Hologic equivalents. To establish the relationship between the two measurements, 180 osteopenic subjects referred to the metabolic bone disease clinic had vertebral BMD measurements made on the same day, but on both densitometers. As expected, a strong correlation existed between the two measurements (r = 0.96), described by the following equation; Hologic (g/ cm2) = 0.825 X Lunar (g/cm2) -0.0 18. The standard error of the estimate for the regression line was 0.045 g/cm2. The relationship between the Hologic and Lunar instruments in this center is similar to that described by Gluer et al. (26) . Thus the baseline BMD data for the Control patients have been converted to Hologic BMD equivalents (see Table I ).
Serum samples for biochemistry were obtained at baseline on day 0; after 12 and 24 h of the PTH infusion during day 0, and thereafter on days 14 and 28 of PTH injections, on days 40 and 70 during calcitonin/ placebo injections, and at the end of the cycle on day 90 (samples obtained fasting, between 08:00 and 10:00 h, and predose). To determine the calcemic response to 800 IU equivalents of hPTH given subcutaneously, serum calcium levels were measured pre-, 1, 4, and 8 h postinjection on day 4 of PTH injections. Fasting 2-h urine samples were collected on the same days and at the same times as the serum samples. All urinary biochemical values are expressed in units of excretion per liter glomerular filtration (GF) (27) .
Serum calcium (Ca), creatinine, and alkaline phosphatase (AP) were measured by standard automated methodology. Serum osteocalcin (OC) was measured by radio immunoassay (IncStar Corp., Stillwater, MN), with a normal reference range of 1.80-6.50 jg/liter; the within and between assay coefficient of variation (CV) was ±5.3% and 4.5%, respectively. Serum PICP was measured by RIA (IncStar Corp.) with a normal reference range of 64-275 ,ug/liter; the within and between assay CV was ±6.5% and ±8.0%, respectively. Serum immunoreactive parathyroid hormone (i-PTH) was measured by a two-site radio immunometric assay (IncStar Corp.) with a normal reference range of 0.5-5.0 pmol/liter. There is no cross-reactivity in this assay with the ( 1-34) amino-terminal hormone fragment. Urinary hydroxyproline (OH-Pro) was measured by a colorimetric assay (28) tion of deoxypyridinoline (deoxy-PYR) was measured by a modification of the method described by Black et al. (30) with a normal reference range of < 2.57 pmol/liter GF. Briefly 250-pil aliquots of urine were hydrolyzed with an equal volume of concentrated HCl at 11 50C for 2 h in a domestic pressure cooker. The cross-links were extracted from the hydrolysates over cellulose (30) and then subjected to reversephase HPLC using a Nova Pak C18 column (Waters Millipore, Mississauga, ON, Canada), eluted with a gradient of 12-25% CH3CN in water at 1 ml/min over 14 min, 10 mM heptafluoro-butyric acid being used as an ion-pairing reagent. The column was monitored using a model M470 fluorescence detector (Waters) operating at an excitation wavelength of 295 nm and an emission wavelength of 390 nm. The within and between assay CV was ±5.5%, and ±8.0% for deoxypyridinoline. is the urinary concentration of the analyte per liter of urine. This also has the advantage of correcting the data for natural age-related declines in GFR seen in these elderly subjects, whose creatinine clearance estimates ranged from 0.72 to 1.49 ml/s (mean 1.02±0.31). Whether expressed by the more conventional referent (per millimole creatinine) or per liter of GF, the coefficients ofvariance ofthe urinary excretion data were comparable.
Trans-iliac crest bone biopsies were obtained in the 20 osteoporotic patients from this report immediately after completing the 28-d course of PTH injections. The tetracycline skeletal markers used to calculate bone formation rates were given 14 d apart, the first label coinciding with the midpoint of the treatment period, and the second label with the end of PTH therapy. Because it was not possible to obtain baseline bone biopsies from this group ofpatients, the bone histomorphometric results were compared with baseline bone biopsies obtained in 15 osteoporotic women aged 65±5 yr, who have been previously reported in an earlier clinical trial evaluating cyclical parathyroid hormone and calcitonin therapy (8) . Bone histomorphometric parameters were measured as previously described (8) . Quantitative histomorphometry over the cancellous surfaces was performed using the Bioquant Version 4 Software (Bioquant, Nashville, TN); the measured and derived parameters conform to the standard nomenclature and formulas recommended by the subcommittee on bone histomorphometry ofthe American Society for Bone and Mineral Research ( 31 ). The static histomorphometric parameters included total bone volume per tissue volume (BV/TV, %), osteoid volume per bone volume (OV/BV, %) the active osteoid surface lined by cuboidal osteoblasts (ObS/OS, %), the number of osteoblasts per unit cancellous surface (NOb/BS,cm), the total erosion surface (ES/BS, %), the total number of osteoclasts per unit surface (NOc/BS,cm). Both double and single tetracycline-labeled surfaces (dLS/BS, %, and sLS/BS, %) were measured to obtain the mineralizing surface (MS/BS, %) using the correction for "label escape" (dLS + 1/2 sLS).
Dynamic parameters included the following: the mineral apposi- 
Results
In that it was necessary to compare the bone histomorphometric data in the study patients to an independent control group, the baseline demographic and biochemical data were carefully evaluated in both groups. This is shown in Table I . The study and control groups were not statistically different with respect to age, sex, height, weight, daily calcium intake, number of vertebral fractures, or degree of osteopenia (assessed by vertebral BMD). Within the 3 mo before entering the present study, two patients ( 10%) had been taking estrogen replacement (Premarin 0.625 mg daily), three patients (15%) a thiazide diuretic, seven patients (35%) a calcium supplement (< 750 mg of elemental calcium), and two patients (10%) thyroxine replacement (0.1 mg of L-thyroxine daily). In contrast, the control group contained one patient (7%) on estrogen replacement, two patients ( 13%) on thiazides, three patients (20%) on calcium supplements, and two patients ( 13%) on thyroxine replacement. There were no differences between the two treatments' subgroups with respect to these medications.
As can be seen in Table I , there were small but statistically significant differences between some of the available baseline biochemical parameters in the two groups (for serum calcium, AP and urinary calcium excretion); serum osteocalcin and urinary OH-Pro excretion were similar. Neither serum P1 CP nor i-PTH data by a comparable assay were available for the control group. Data are mean±SD.
* P < 0.05, between the two groups.
Vertebral BMD data in control group measured by dual photon densitometry and shown converted to dual energy x-ray equivalent values (see Methods). Table II shows the baseline characteristics for the two subgroups within the present study patients at entry (baseline). Since all patients went through an identical protocol with respect to the PTH infusion, and the first 28 d of PTH injections, the data in Table II are shown for the whole group of 20 patients, as well as by the two group allocations. There are no significant differences, in age, or baseline biochemical characteristics, between the two groups.
Effects ofPTH infusion. During the initial PTH infusion, total serum calcium levels for all 20 patients increased from 2.35±0.11 to 2.72±0.13 mmol/liter (P < 0.001) whereas urinary cyclic AMP increased from 24.6±1 1.1 to 41.1±15.5 nmol/liter GF (P < 0.01). Changes in serum markers of bone formation (AP, osteocalcin, and P1 CP) and urinary markers of bone resorption (calcium, OH-Pro, and Deoxy-PYR) across the 24 h PTH infusion are shown in Fig. 1 . Serum AP fell progressively by a total of9% from 75±27 to 68±25 IU/liter (P < 0.05), whereas serum osteocalcin fell by 39% from 1.94±1.36 to 1.19±1.13,4g/liter(P < 0.01), and serum PICP fell by 49% from 168±144 to 86±63,4g/liter (P < 0.01). Conversely, fasting urinary calcium excretion increased by 52% from 0.027±0.013 to 0.041±0.034 mmol/liter GF (P < 0.02), urinary OH-Pro increased by 48% from 2.40±1.49 to 3.56±1.02 be/liter GF (P < 0.01). Although urinary deoxy-PYR increased by 5% from 0.76±0.75 to 0.80±0.57 pmol/liter GF, this difference was not significant (P = 0.50).
Effects of PTH and calcitonin injections. Serum calcium levels measured on the 4th d of PTH injections were as follows: phosphatase) were seen 24 h after the second PTH injectiondata not shown. The maximum increases occurred by the end of the period of PTH therapy, and the mean values equaled or exceeded the upper limits of the normal reference ranges for young adults. By ANOVA, the decline in all three markers of bone formation after cessation of PTH therapy was significant across time (P < 0.001), but there was no significant time x group interaction, and no significant overall differences were seen in the group receiving calcitonin therapy between days 28 and 70, even though calcitonin therapy in group 2 resulted in an apparently earlier decline in serum osteocalcin levels (Fig.  2) . However, both AP and OC levels were still significantly higher than baseline by day 90 (P < 0.01 adjusted for the seven time points of measurement by Bonferroni's correction.) Fig. 3 shows the changes in urinary markers ofbone resorption. All urine data are recorded from fasting 2-h collections, and expressed per liter GF. ANOVA indicated significant increases in urine calcium (P < 0.003) and OH-Pro (P < 0.001) but the increases in deoxy-PYR were not significant (P = 0.53) during the action in urine OH-Pro excretion (P = 0.027); post hoc analysis indicated a significantly lower OH-Pro excretion by day 42 in group 2, during calcitonin therapy (adjusted P < 0.05). However, calcitonin had no significant effects at other time points, or in either of the other urinary biochemistries.
Bone histomorphometry. (Table IV A ). There were no significant correlations with urine deoxy-PYR. There were significant correlations between serum osteoDiscussion calcin levels measured on day 28 and several histomorphometric parameters ofmineralisation and bone formation (Table IV The evaluation of the biochemical changes in serum and uri-B), but fewer correlations with serum P1CP, and no correlanary markers of bone turnover supported the initial hypothesis tions with serum AP. Only urine OH-Pro excretion correlated that continuous intravenous infusion of PTH ( 1-34) might act with the histologic measurement of surface osteoclast counts.
to depress bone formation. Conversely intermittent daily subNo correlations were seen with any histologic measurement of cutaneous injections of this hormone resulted in a markedly bone resorption and either urine calcium or deoxy-PYR. anabolic action, confirmed by both biochemical and histologi- cal evidence. Both routes of hormone delivery led to increased bone resorption. Compared to the changes in biochemical markers ofbone turnover seen after PTH ( 1-34) therapy, calcitonin had a limited impact on selected markers ofbone resorption, suggesting that this hormone will have a minimal synergistic role to play in the development of combined anabolic/ antiresorptive protocols of osteoporosis therapy. When exposed to PTH in tissue culture, osteoblast-like cells typically respond by a reduced secretion ofboth AP ( 18, 19, 32, 33) and OC (20, 2 1 ), suggesting that PTH inhibits matrix synthesis. In this study, continuous intravenous infusion of PTH ( 1-34) also led to significantly reduced circulating levels of AP, OC, and PlCP. This confirms our earlier finding that both PTH (1-34) and PTH-related peptide infusion in young healthy subjects resulted in reduced circulating osteocalcin levels (34) and that of Riggs et al. (35) , who also found reduced serum osteocalcin levels after infusion of PTH ( 1-34) in young normal controls.
OC levels exhibit a diurnal variation with peak serum concentrations occurring in the late afternoon and a nadir in midmorning (36) . It is unlikely that the fall in serum osteocalcin levels seen after 12 h of infusion were attributable to diurnal variation in that such a fall was asynchronous with the anticipated peak in diurnal levels, while the 24-h nadir was significantly lower than the baseline obtained at the same time on the previous day. We advanced similar arguments about the effects of both PTH and parathyroid hormone-related peptide infusion in young healthy adults (34). It is equally unlikely that diurnal variations in serum AP and P1CP explain the observed responses during PTH infusion. However this question can only be resolved definitively by observing the changes in these parameters in age-and sex-matched osteoporotic patients infused with vehicle alone; this was not an option we were able to pursue in this study protocol.
These findings are consistent with the conclusion that continuous exposure to PTH leads to suppression of osteoblast matrix synthesis. However other explanations are valid, including the possibility that continuously high levels of PTH alter osteoblast release of these proteins to the extracellular fluid, or selectively modify the synthesis of some intracellular proteins without impacting on osteoid matrix production.
It is most unlikely that experimental histological confirmation ofthis anti-anabolic action of PTH will ever be available in humans. Nonetheless histological studies after continuous PTH infusion in both dogs (37, 38) and rats ( 1) clearly show that the effects are primarily of increased bone resorption or increased activation frequency of remodeling, with no evidence for increased bone formation. The natural experiment in humans subjected to continuously increased levels of PTH is represented by primary hyperparathyroidism. However, this state is clearly different from that of exogenous infusion, because patients with endogenous hyperparathyroidism frequently have increased circulating markers of bone formation including AP and OC (39, 40) , and bone biopsies usually demonstrate evidence of increased bone formation (41, 42) . Thus patients with primary hyperparathyroidism have more similarities to the findings in subjects given intermittent PTH injections, as discussed below.
During the 28 d of subcutaneous PTH injections, there were striking increases in serum AP (by 104% ofbaseline), OC (259%) and PICP (140%), to levels that clearly exceed the upper limits of the normal ranges for these markers. The responses in bone formation markers appear to be dose dependent. In a pilot study of a cyclical protocol using half the dose and duration of PTH injections, Hodsman et al. (7) reported increases in AP and OC of only 25% and 72%, respectively. In another cyclical treatment protocol, utilizing 400 IU equivalents PTH ( 1-38) daily for 70 d at a time, Hesch et al. (5) found a progressive increase in AP of 40% during the first year, whereas Reeve et al. (2) reported only a 15% increase using continuous daily dosing of 500 IU equivalents PTH . These changes may represent increased bone matrix synthesis and mineralization in the skeleton.
In a recent consensus development conference on osteoporosis, the value of serum and urinary markers of bone formation and resorption was discussed. In particular, serum OC appeared to be the most sensitive marker of bone turnover when bone formation and resorption are coupled, and of bone formation whenever bone formation and resorption are uncoupled (as may well be the case in the present study) (43) . Serum levels of AP and P1CP appear to provide similar information (43, 44) . Direct confirmation of this can be inferred from the bone biopsies obtained at the end of the period of PTH injections. Thus the osteoid volume (OV/BV), active osteoid surfaces, (ObS/OS and NOb/BS), double-labeled tetracycline surface (dLS/ BS), and bone formation rates (BFR/ BS) were two-to fivefold increased over those obtained in control biopsies in osteoporotic women (Table III) .
It is difficult to compare the histomorphometric findings in these biopsies with previously published data. Few authors have attempted to quantitate very early changes in response to PTH therapy. Hodsman et al. (8) showed an insignificant increase ( 17%) in BFR/BS after two 3-mo cycles of sequential PTH/calcitonin therapy, but the activation frequency increased significantly by twofold, which is similar to the high remodeling activation frequency observed in the current study. However, this earlier study used only 25% of the cumulative doses of PTH in each treatment cycle. The dynamic histomorphometric data of Reeve et al. (2) , obtained from iliac biopsies in PTH-treated patients after 6-24 mo of daily injections are unfortunately not comparable to the data reported here due to differences in histomorphometric techniques. However, it would appear that the patients reported by Reeve et al. (2) received 500 U PTH ( 1-34) daily and increased osteoid forming surfaces by -50% over the long term (2) . All other reported studies ofthe anabolic effects ofPTH have utilized longterm changes in BMD as the outcome measurement, and are therefore not comparable to the data reported here.
It was not possible to evaluate bone histomorphometric data in this study against an internal control, with each patient serving as her own control (by having a pretreatment bone biopsy). It was therefore necessary to compare histologic findings against an independent control group. As can be seen in Table I , the demographic data between the two groups of subjects suggest they were indeed well matched clinically. Indeed the inclusion and exclusion criteria for entry into both studies (the pilot study and current study) were identical. However there were significant baseline differences in serum biochemistry between the two groups. Thus the control group had significantly lower serum calcium, higher serum AP, and higher urinary calcium excretion levels than the current study group. Since fewer individuals within the control group were taking calcium supplements on entry to the pilot study, some ofthese findings might be explained by higher endogenous PTH secretion in the control group. Unfortunately changes in the i-PTH assay methodology between the two groups do not allow this hypothesis to be tested. However, it should be stressed that if the control group did have relatively higher endogenous i-PTH levels, the bone histomorphometric data would have been biased against finding significant differences between the two groups ofbone biopsies. Despite this potential bias, the levels of significance between the two groups are so consistent that it is difficult to ascribe another explanation for the differences other than the effects of exogenous PTH therapy.
Of the three formation markers, serum osteocalcin demonstrated the largest responses to PTH therapy, and correlated significantly with serum AP (r = 0.49) but not with P1 CP (r = 0.25) and with several histological markers of bone formation, including the derived calculation of bone formation rate (Table IV However the 53% increase in urine OH-Pro is clearly less pronounced than the percentage increases in bone formation markers, suggesting that bone formation is the dominant response to intermittent PTH therapy. The increases in histological parameters of bone resorption and the gradual increase in urine OH-Pro excretion are consistent with the progressive recruitment of new bone multicellular units (BMUs) as bone remodeling is activated by PTH. Indeed, using the classical BMU-based derivational formulae for calculating the activation frequency of bone remodeling over previously quiescent surfaces, the bone biopsy data demonstrated a twofold increase in activation frequency over the control group ofbiopsies. However some caution is needed to interpret the activation frequency calculation, which assumes that bone formation is coupled in time and space to a preexisting resorption site. In this series of biopsies, it is difficult to envision that the two-to threefold increase in double-tetracycline labels (representing bone formation) is a consequence of coupled bone resorptionformation, as is predicted by current concepts ofbone remodeling. The first tetracycline label was given after only 14 d ofPTH therapy, before any significant increase in hydroxy-prolinuria (see Fig. 3 ). If the increase in bone forming surfaces had been coupled to preexisting resorption sites, then the time frame of recruitment for both osteoclasts and osteoblasts must have been very truncated. The biochemical time course of the putative markers for bone formation and resorption are consistent with the cellular events occurring in bone in an uncoupled fashion (i.e., both events might be occurring on previously quiescent surfaces). Nonetheless we postulate this hypothesis with considerable caution since the relative magnitudes of the histomorphometric changes are being compared with an independent group of control biopsies, which were not obtained from a patient population who were randomly assigned within the current study.
The changes in deoxy-PYR excretion were not striking. Deoxy-PYR is a cross-linked lysylpyridinoline which is released during collagen degradation and is relatively specific of the break-down of bone collagen (22, 50) . There is evidence that 24-h excretion of deoxy-PYR is more sensitive than OHPro as a marker ofbone turnover in both normal and abnormal bone metabolism (22) (23) (24) . That we could not confirm the utility of deoxy-PYR as a better marker of bone resorption than OH-Pro may have been due to the choice of fasting urine samples, rather than a full 24-h urine collection. However, previous reports have suggested that fasting urinary deoxy-PYR measurements have proven to be significant predictors ofbone turnover and resorption (51, 52) . Finally, we assessed the impact of sequential calcitonin therapy on the biochemical markers of bone turnover. As can be seen in Fig. 2 , calcitonin did not affect the course of the bone formation markers which gradually declined toward baseline once PTH therapy was stopped; the apparent attenuation ofthe serum osteocalcin response was not significant. There was a modest attenuation in the bone resorption markers during calcitonin therapy, which was significant only for OH-Pro excretion (Fig. 3) . Similar results were reported in our earlier report of a PTH/calcitonin protocol (7) . We conclude from these two studies that the addition of calcitonin appears to confer no obvious advantages as assessed by biochemical responses reflecting skeletal turnover. Indeed the potent effects of PTH as both an anabolic and activation agent may make therapy with this hormone relatively feasible if it can be given alone for several short cyclical courses a year rather than by continuous daily injections. The present study is designed to follow bone mineral density responses over eight such cycles in an expanded trial which should provide a more definitive outcome to this question.
In conclusion, we have reported the biochemical responses to both continuously infused, and intermittently injected PTH ; although PTH appears to be anti-anabolic when administered by infusion, it has strongly anabolic actions when given by intermittent injections. Serum osteocalcin levels and urine OH-Pro excretion appeared to be the most sensitive respective biochemical markers of bone formation and resorption. Bone histomorphometric studies at the end of the 28-d period of PTH (1-34) injections suggested that PTH was indeed a potent activator of bone remodeling but, in addition, resulted in osteoid matrix synthesis which may have occurred de novo on quiescent cancellous bone surfaces.
